TP53 and breast cancer: We assume that primary breast cancer with high SUV is a characteristic of aggressiveness originated from the p53 alteration, but it seems unlikely that the immunohistochemical measurement of p53 could sufficiently provide clinically useful results because it does not exhibit p53 nonsense point mutations or deletions in p53[31,32].